78 related articles for article (PubMed ID: 19906198)
1. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
2. Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains.
Abendstein L; Dijkstra DJ; Tjokrodirijo RTN; van Veelen PA; Trouw LA; Hensbergen PJ; Sharp TH
Nat Commun; 2023 Jul; 14(1):4027. PubMed ID: 37419978
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Human IgG Subclass and Allotype on Complement Activation.
Damelang T; de Taeye SW; Rentenaar R; Roya-Kouchaki K; de Boer E; Derksen NIL; van Kessel K; Lissenberg-Thunnissen S; Rooijakkers SHM; Jongerius I; Mebius MM; Schuurman J; Labrijn AF; Vidarsson G; Rispens T
J Immunol; 2023 Dec; 211(11):1725-1735. PubMed ID: 37843500
[TBL] [Abstract][Full Text] [Related]
4. Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation.
Lu Y; Harding SE; Michaelsen TE; Longman E; Davis KG; Ortega A; Grossmann JG; Sandlie I; García de la Torre J
Biophys J; 2007 Dec; 93(11):3733-44. PubMed ID: 17704171
[TBL] [Abstract][Full Text] [Related]
5. The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.
Rayner LE; Hui GK; Gor J; Heenan RK; Dalby PA; Perkins SJ
J Biol Chem; 2015 Mar; 290(13):8420-38. PubMed ID: 25659433
[TBL] [Abstract][Full Text] [Related]
6. Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies.
Olafsen T; Munthe Lund CK; Bruland OS; Sandlie I; Michaelsen TE
Cancer Immunol Immunother; 1999 Oct; 48(7):411-8. PubMed ID: 10501855
[TBL] [Abstract][Full Text] [Related]
7. Coming together at the hinges: Therapeutic prospects of IgG3.
Chu TH; Patz EF; Ackerman ME
MAbs; 2021; 13(1):1882028. PubMed ID: 33602056
[TBL] [Abstract][Full Text] [Related]
8. IgG subclasses and allotypes: from structure to effector functions.
Vidarsson G; Dekkers G; Rispens T
Front Immunol; 2014; 5():520. PubMed ID: 25368619
[TBL] [Abstract][Full Text] [Related]
9. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
Challa DK; Velmurugan R; Ober RJ; Sally Ward E
Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104
[TBL] [Abstract][Full Text] [Related]
10. Isotype and glycoform selection for antibody therapeutics.
Jefferis R
Arch Biochem Biophys; 2012 Oct; 526(2):159-66. PubMed ID: 22465822
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes.
Ramsland PA; Farrugia W; Bradford TM; Sardjono CT; Esparon S; Trist HM; Powell MS; Tan PS; Cendron AC; Wines BD; Scott AM; Hogarth PM
J Immunol; 2011 Sep; 187(6):3208-17. PubMed ID: 21856937
[TBL] [Abstract][Full Text] [Related]
12. Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity.
Gavin AL; Barnes N; Dijstelbloem HM; Hogarth PM
J Immunol; 1998 Jan; 160(1):20-3. PubMed ID: 9551950
[TBL] [Abstract][Full Text] [Related]
13. Complement is activated by IgG hexamers assembled at the cell surface.
Diebolder CA; Beurskens FJ; de Jong RN; Koning RI; Strumane K; Lindorfer MA; Voorhorst M; Ugurlar D; Rosati S; Heck AJ; van de Winkel JG; Wilson IA; Koster AJ; Taylor RP; Saphire EO; Burton DR; Schuurman J; Gros P; Parren PW
Science; 2014 Mar; 343(6176):1260-3. PubMed ID: 24626930
[TBL] [Abstract][Full Text] [Related]
14. Impact of structural modifications of IgG antibodies on effector functions.
Damelang T; Brinkhaus M; van Osch TLJ; Schuurman J; Labrijn AF; Rispens T; Vidarsson G
Front Immunol; 2023; 14():1304365. PubMed ID: 38259472
[TBL] [Abstract][Full Text] [Related]
15. Avidity in antibody effector functions and biotherapeutic drug design.
Oostindie SC; Lazar GA; Schuurman J; Parren PWHI
Nat Rev Drug Discov; 2022 Oct; 21(10):715-735. PubMed ID: 35790857
[TBL] [Abstract][Full Text] [Related]
16. The role of naturally acquired antimalarial antibodies in subclinical Plasmodium spp. infection.
O'Flaherty K; Roe M; Fowkes FJI
J Leukoc Biol; 2022 May; 111(5):1097-1105. PubMed ID: 35060185
[TBL] [Abstract][Full Text] [Related]
17. Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies.
Chu TH; Crowley AR; Backes I; Chang C; Tay M; Broge T; Tuyishime M; Ferrari G; Seaman MS; Richardson SI; Tomaras GD; Alter G; Leib D; Ackerman ME
PLoS Pathog; 2020 Feb; 16(2):e1008083. PubMed ID: 32092122
[TBL] [Abstract][Full Text] [Related]
18. Igh locus structure and evolution in Platyrrhines: new insights from a genomic perspective.
Garzón-Ospina D; Buitrago SP
Immunogenetics; 2020 Apr; 72(3):165-179. PubMed ID: 31838542
[TBL] [Abstract][Full Text] [Related]
19. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody.
Gulati S; Beurskens FJ; de Kreuk BJ; Roza M; Zheng B; DeOliveira RB; Shaughnessy J; Nowak NA; Taylor RP; Botto M; He X; Ingalls RR; Woodruff TM; Song WC; Schuurman J; Rice PA; Ram S
PLoS Biol; 2019 Jun; 17(6):e3000323. PubMed ID: 31216278
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
